Emanuel Petricoin Discusses Tumor Heterogeneity

Emanuel F. Petricoin, III, PhD
Published: Thursday, Mar 28, 2013

Emanuel F. Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses tumor heterogeneity in patients with breast cancer.

Reports of tumor heterogeneity within patients suggest that different biopsies present different information to a patient or physician.

There are new trials however looking at signaling architecture with relation to tumor heterogeneity. These trials have shown that signaling architecture is more stable than the genomic profile, which is beneficial from a functional standpoint.
 
Emanuel F. Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses tumor heterogeneity in patients with breast cancer.

Reports of tumor heterogeneity within patients suggest that different biopsies present different information to a patient or physician.

There are new trials however looking at signaling architecture with relation to tumor heterogeneity. These trials have shown that signaling architecture is more stable than the genomic profile, which is beneficial from a functional standpoint.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x